Search clinical trials for: nivolumab, ipilimumab

Total 1951 results

Fox Chase Cancer Center
Incuron

Suspended

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Locally Advanced or Metastatic Melanoma

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Adrenocortical Carcinoma | Penile Cancer | Genitourinary Cancer | Non-urothelial Bladder | Non-urothelial Upper Tract | Non-adenocarcinoma Prostate Cancer | Refractory Germ-cell | High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma

United States
Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb

Completed

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States
Massachusetts General Hospital
Bristol-Myers Squibb

Completed

Ipilimumab and Nivolumab in Leptomeningeal Metastases

Leptomeningeal Carcinomatosis

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma (CheckMate 800)

Renal Cell Carcinoma

United States, Australia, Chile
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Nivolumab Plus Ipilimumab in Thyroid Cancer

Thyroid Cancer

United States
ETOP IBCSG Partners Foundation
Bristol-Myers Squibb; Intergroupe Francophone de Cancerologie Thoracique; Frontier... and other collaborators

Unknown

Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease (STIMULI)

Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer

Switzerland, France, Spain, Germany, United Kingdom, Netherlands, Australia, Belgium
University Hospital Tuebingen

Terminated

Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma

Metastatic Melanoma | Brain Metastases

Germany
Jason J. Luke, MD

Recruiting

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Melanoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | Cholangiocarcinoma | Bladder Cancer | Renal Cancer | Anal Cancer | Merkel Cell Carcinoma | HNSCC

United States
Brown University
The Miriam Hospital; Rhode Island Hospital

Active, not recruiting

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

Melanoma

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb; Exelixis

Recruiting

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Renal Cell Carcinoma | Brain Metastases

United States
The Netherlands Cancer Institute
4SC

Active, not recruiting

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)

Malignant Melanoma Stage III

Netherlands
NYU Langone Health

Active, not recruiting

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Bristol-Myers Squibb

Terminated

A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

Renal Cell Carcinoma

Canada, United States
Incyte Biosciences International Sàrl

Completed

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Advanced Malignancies

United States
Elizabeth Davis
Bristol-Myers Squibb

Terminated

Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

Metastatic Melanoma | Advanced Melanoma | Metastatic Melanoma Stratified by MHC-II Expression

United States
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (PIVOT-02)

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Urothelial Carcinoma | HR+/HER2- Breast Cancer

United States, Spain, Canada, France, Italy, Belgium, Poland, United Kingdom
Hospital das Clínicas de Ribeirão Preto
Bristol-Myers Squibb; Fundação de Amparo à Pesquisa do Estado de São Paulo

Recruiting

CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy

Renal Cancer Metastatic

Brazil
Asylia Diagnostics BV

Recruiting

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Melanoma | Lung Cancer

Belgium
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Relapsed Hodgkin's Disease, Adult

United States
Hackensack Meridian Health

Active, not recruiting

Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001)

Lymphoma | Multiple Myeloma

United States
Greg Durm, MD
Bristol-Myers Squibb; Big Ten Cancer Research Consortium

Active, not recruiting

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Hatim Husain

Active, not recruiting

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (NSCLC)

Advanced NSCLC

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 714)

Head and Neck Cancer

United States, Brazil, Italy, South Africa, Spain, Canada, Argentina, Belgium, Chile, Czechia, Finland, France, Ireland, Mexico, Netherlands, Norway, Romania, Russian Federation, Sweden, Turkey, United Kingdom
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Suspended

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Non-small Cell Lung Cancer

United States
Sarah Sammons, MD
Bristol-Myers Squibb; Duke University

Terminated

Neoadjuvant Immunotherapy in Brain Metastases

Brain Metastases, Adult

United States
Bristol-Myers Squibb

Withdrawn

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA)

Melanoma

France, Italy, Poland, United States, Brazil, Spain, Australia, Denmark, Germany, Austria, Netherlands, Russian Federation, Belgium, United Kingdom, Sweden, Switzerland
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
Rampart Health, L.L.C.

Completed

A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

Metastatic Prostatic Adenocarcinoma

United States
SQZ Biotechnologies

Terminated

Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Adult Solid Tumor

United States
Ludwig Institute for Cancer Research
Bristol-Myers Squibb; Conquer Cancer Foundation

Completed

Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma

Melanoma

United States
Dana-Farber Cancer Institute
Gateway for Cancer Research

Recruiting

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Epithelioid Sarcoma | Atypical Teratoid/Rhabdoid Tumor | Malignant Rhabdoid Tumor | Rhabdoid Tumor of the Kidney | Chordoma (Poorly Differentiated or De-differentiated) | Other INI1 Negative Tumors (With PI Approval) | Other SMARCA4-deficient Malignant Tumors (With PI Approval)

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Bladder Cancer

United States
National Cancer Institute (NCI)

Recruiting

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Metastatic Solid Tumors | Treatment-Refractory Cancers

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Breast Cancer

United States
Toni Choueiri, MD
Bristol-Myers Squibb

Active, not recruiting

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

Renal Cancer

United States
Suthee Rapisuwon
Bristol-Myers Squibb

Active, not recruiting

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Melanoma | Ocular Melanoma

United States
European Organisation for Research and Treatment...

Terminated

Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer (CRUCIAL)

Inoperable œsophageal Cancer

Spain, France
Abramson Cancer Center of the University of Pennsylvania

Terminated

Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

Mucinous Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon

United States
National Cancer Centre, Singapore
National University Hospital, Singapore; Johns Hopkins Singapore

Terminated

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Singapore
ExcellaBio LLC

Terminated

Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

Gastric Cancer | Ovarian Cancer | Breast Cancer Female

United States
Kidney Cancer Research Bureau

Unknown

Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

Renal Cell Carcinoma

Russian Federation
Massachusetts General Hospital
William M. Wood Foundation

Recruiting

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Skin Cancer | Metastatic Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Jazz Pharmaceuticals

Terminated

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Small-cell Lung Cancer | Relapsed Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer

United States
Case Comprehensive Cancer Center

Completed

Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

Metastatic Renal Cell Carcinoma

United States
University of Erlangen-Nürnberg Medical School

Completed

Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition (ST-ICI)

Metastatic Cancer

Germany
NYU Langone Health

Completed

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

GBM | MGMT-unmethylated Glioblastoma (GBM)

United States
Washington University School of Medicine
NovoCure Ltd.

Terminated

Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

Melanoma With Brain Metastasis

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Active, not recruiting

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Metastatic Melanoma | Metastasis to Brain

United States

Search clinical trials for: nivolumab, ipilimumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations